Analyst Update: Alexion, Vertex Pharma, and Vitae Pharma

Analysts adjusted their ratings and price targets on Alexion Pharmaceuticals, Inc. (ALXN), Vertex Pharmaceuticals Incorporated (VRTX), and Vitae Pharmaceuticals Inc (VTAE)

Mar 18, 2016 at 2:32 PM
facebook X logo linkedin


Analysts are weighing in on drugmakers Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), and Vitae Pharmaceuticals Inc (NASDAQ:VTAE). Here's a quick roundup of today's brokerage notes on ALXN, VRTX, and VTAE.

  • ALXN saw its price target trimmed to $216 from $217 at Leerink, but is 0.7% higher at $128.82 amid broad-market tailwinds. However, the stock is a long-term laggard, and just yesterday notched a two-year low of $124.16. More bearish brokerage attention could come down the pike if Alexion Pharmaceuticals, Inc. fails to turn things around. After all, 14 of 18 brokerages rate the stock a "buy" or better, with not a single "sell" opinion in sight. Plus, ALXN's average 12-month price target of $200.26 represents a 55.5% premium to current levels.
  • VRTX is up 3.8% at $82.21, despite a price-target cut to $135 from $145 at RBC. It hasn't been this pretty for all of 2016, as the shares have surrendered over 34% of their value year-to-date. Traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have been rolling the dice on extended losses in recent months. Specifically, lightly traded Vertex Pharmaceuticals Incorporated's 50-day put/call volume ratio of 2.44 sits just 6 percentage points from a 12-month peak.
  • Rounding things out, VTAE has surged 5.7% to trade at $7.18, boosted by a price-target hike to $23 from $20 at Wedbush -- territory not charted since December 2014. In fact, the stock is on track to close above its 20-day moving average for the first time since gapping lower earlier this month on a poorly received quarterly earnings report. This represents quite a comeback for Vitae Pharmaceuticals Inc, which hit a record low earlier this week. While shareholders may be happy with the rebound, short sellers probably aren't. Over 15% of VTAE's float is sold short, representing nearly four weeks' worth of trading activity, at its average trading volume.
For other stocks in analysts' crosshairs, read Analyst Upgrades: Adobe Systems Incorporated, Chevron Corporation, and Wynn Resorts, Limited and Analyst Downgrades: Valeant Pharmaceuticals Intl  Inc, Micron Technology, Inc., and PayPal Holdings Inc.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI